BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38558374)

  • 1. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
    Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
    Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
    Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
    Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
    Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
    Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
    Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
    Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
    Pellini B; Chaudhuri AA
    J Clin Oncol; 2022 Feb; 40(6):567-575. PubMed ID: 34985936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
    Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
    Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
    Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
    Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
    J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
    J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
    Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.